BiotechTube
Pulmotect

Pulmotect

Houston, United States· Est.
pulmotect.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $7.8M

Overview

Pulmotect is advancing PUL-042, an inhaled innate immune stimulant with a unique mechanism of action offering immediate, broad-spectrum protection against respiratory pathogens. The asset has completed Phase 1/2a trials demonstrating safety and proof-of-concept antiviral activity, with Phase 2 studies planned for immunocompromised cancer patients and other at-risk groups. The company is privately held, led by an experienced management and board with deep expertise in drug development, and is positioned to address a significant market opportunity in preventative respiratory care.

Infectious DiseasePulmonologyOncology Supportive Care

Technology Platform

Inhaled combination of synthetic TLR agonists (TLR2/6 and TLR9) designed to stimulate the innate immune system in the lungs, providing broad-spectrum protection against viral, bacterial, and fungal pathogens.

Funding History

2
Total raised:$7.8M
Grant$2.3M
Series A$5.5M

Opportunities

A significant opportunity exists in addressing the high unmet need for effective prophylaxis against respiratory infections in immunocompromised cancer patients, a population with limited options and poor outcomes.
The broad-spectrum, pathogen-agnostic mechanism also positions the platform well for pandemic preparedness and combating antimicrobial resistance.
Success in initial oncology trials could pave the way for expansion into other large, at-risk populations like COPD and asthma patients.

Risk Factors

The primary risk is clinical failure in upcoming Phase 2 trials to demonstrate robust efficacy in preventing infections or improving patient outcomes.
The company also faces regulatory uncertainty for a novel immunostimulant prophylactic and significant financing risk to fund costly late-stage clinical development.
Competition from other prophylactic approaches, including advanced vaccines and antimicrobials, presents a commercial challenge.

Competitive Landscape

Pulmotect operates in a niche but competitive space. Direct competitors include other companies developing innate immune stimulants or host-directed therapies for infection prevention. It also faces indirect competition from advanced vaccine platforms, long-acting monoclonal antibodies, and novel antimicrobials. Its key differentiator is the localized, inhaled delivery of a broad-spectrum protective stimulus, a unique approach compared to pathogen-specific strategies.

More companies in Immunotherapy / Immuno-Oncology →More companies in United States →